- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Authors
Keywords
-
Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 44, Issue 4, Pages 222-236
Publisher
Elsevier BV
Online
2023-02-23
DOI
10.1016/j.tips.2023.01.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer
- (2022) Bing Yan et al. BMC GASTROENTEROLOGY
- Immune phenotypic linkage between colorectal cancer and liver metastasis
- (2022) Yedan Liu et al. CANCER CELL
- The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer
- (2022) Kazuhiro Nagao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2022) Carlotta Antoniotti et al. LANCET ONCOLOGY
- Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
- (2022) Ori Hassin et al. Nature Communications
- Exploring immunotherapy in colorectal cancer
- (2022) Junyong Weng et al. Journal of Hematology & Oncology
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
- (2022) Adrià Cañellas-Socias et al. NATURE
- Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
- (2021) Pauline A. J. Mendelaar et al. Nature Communications
- Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression
- (2021) Alexandros Lalos et al. Scientific Reports
- FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
- (2021) Sandra J. Casak et al. CLINICAL CANCER RESEARCH
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
- (2021) Thierry Andre et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- Metastasis-Initiating Cells and Ecosystems
- (2021) Joan Massagué et al. Cancer Discovery
- The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
- (2021) Maurice Michel et al. Cancers
- Tissue-specific tregs in cancer metastasis: opportunities for precision immunotherapy
- (2021) Laura A. Huppert et al. Cellular & Molecular Immunology
- Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
- (2021) Nan Zhang et al. LANCET ONCOLOGY
- Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level
- (2021) Yingcheng Wu et al. Cancer Discovery
- Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
- (2021) Christopher J. Hanley et al. Oncotarget
- A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
- (2021) Ehsan Razeghian et al. Stem Cell Research & Therapy
- Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
- (2021) Hossein Sendi et al. CANCER RESEARCH
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
- (2021) Jie Xu et al. Cell Death & Disease
- Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling
- (2021) Beiping Zhong et al. Cell Death & Disease
- The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis
- (2021) Hiroki Kobayashi et al. GASTROENTEROLOGY
- Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
- (2020) Rong En Tay et al. CANCER GENE THERAPY
- Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer
- (2020) Arianna Fumagalli et al. Cell Stem Cell
- EMT, MET, Plasticity, and Tumor Metastasis
- (2020) Basil Bakir et al. TRENDS IN CELL BIOLOGY
- Myeloid-Derived Suppressor Cells in Colorectal Cancer
- (2020) Izabela Sieminska et al. Frontiers in Immunology
- Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer
- (2020) Dengbo Ji et al. Journal for ImmunoTherapy of Cancer
- Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis
- (2020) Holger Rumpold et al. BMC CANCER
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
- (2020) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
- (2019) Bin Hou et al. DISEASE MARKERS
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance
- (2019) Jonathan Cooper et al. CANCER CELL
- Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors
- (2019) Andreas A. Hombach et al. MOLECULAR THERAPY
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-cancer whole-genome analyses of metastatic solid tumours
- (2019) Peter Priestley et al. NATURE
- Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice
- (2018) Yusuf A. Haggag et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
- (2018) Nicole M. Aiello et al. DEVELOPMENTAL CELL
- The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
- (2018) Wei-Wei Zhang et al. HUMAN GENE THERAPY
- E-cadherin in contact inhibition and cancer
- (2018) Alisha M. Mendonsa et al. ONCOGENE
- Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers
- (2018) Hilla Solomon et al. ONCOGENE
- Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
- (2018) Michael S. Magee et al. Cancer Immunology Research
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
- (2015) S. M. Leto et al. CLINICAL CANCER RESEARCH
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-102 for metastatic refractory colorectal cancer
- (2015) Sean Cleghorn LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fecal microbiota transplantation: in perspective
- (2015) Shaan Gupta et al. Therapeutic Advances in Gastroenterology
- Cancer-Associated Fibroblasts Connect Metastasis-Promoting Communication in Colorectal Cancer
- (2015) Joke Tommelein et al. Frontiers in Oncology
- Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
- (2014) Peter J. Murray et al. IMMUNITY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Mechanisms Governing Metastatic Dormancy and Reactivation
- (2013) Filippo G. Giancotti CELL
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- (2011) Scott Valastyan et al. CELL
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overview of Systemic Therapy for Colorectal Cancer
- (2009) Rachel Goodwin et al. Clinics in Colon and Rectal Surgery
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now